Risk assessment for plant-made pharmaceuticals

CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources

Volumn 2, Issue , 2007, Pages

  Wolt, Jeffrey D ^a   Karaman, Sule ^a   Wang, Kan ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Heterologous gene expression; Industrial protein; Pharmaceutical crop; Plant made vaccine; Recombinant protein; Risk analysis

Indexed keywords

EID: 48849112049     PISSN: None     EISSN: 17498848     Source Type: Journal    
DOI: 10.1079/PAVSNNR20072012     Document Type: Review

References (67)

1. Ma JK-C, Drake PMW, Christou P. The production of recombinant pharmaceutical protein in plants. Nature Reviews Genetics 2003;4:794-805.
2. Goldstein DA, Thomas JA. Biopharmaceuticals derived from genetically modified plants. Quarterly Journal of Medicine 2004;97:705-16.
3. Horn ME, Woodard SL, Howard JA. Plant molecular farming: systems and products. Plant Cell Reporter 2004;22:711-20.
4. Wang K, Chikwamba R, Cunnick J. Plant-based oral vaccines. In: Kaufmann SHE, editor. Novel Vaccination Strategies. Wiley-VCH Verlag, Weinheim, Germany; 2004:387-413.
5. Howard J. The role for edible vaccines. In: Eaglesham A, Carlson C, Hardy RWF, editors. Integrating Agriculture, Medicine and Food for Future Health. National Agricultural Biotechnology Council, Ithaca (NY), USA; 2002:163-76.
6. Stoger E, Vaquero C, Torres E, Sack M, Nicholson L, Drossard J, et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Molecular Biology 2000;42:583-90.
7. Kirk DD, Webb SR. The next 15 years: taking plant-made vaccines beyond proof of concept. Immunology and Cell Biology 2005;83:248-56.
8. Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Molecular Breeding 1997;3:291-306.
9. Morgan MG, Henrion M. Uncertainty: a guide to dealing with uncertainty in quantitative risk and policy analysis. Cambridge Press, Cambridge, UK; 1990.
10. Hayes KR. Best practice and current practice in ecological risk assessment for genetically modified organisms. Canberra, Australia: CSIRO Division of Marine Research 2004. Available from: URL: http://www.environment. gov.au/settlements/publications/biotechnology/ecological-risk/introduction.html - the web site was visited last time on 1 February 2006.
11. Crawford-Brown DJ. Risk-based environmental decisions: culture and methods. Kluwer, Boston; 1999.
12. National Research Council (US). Risk assessment in the federal government: managing the process. National Academy Press, Washington DC, USA; 1983.
13. Wolt JD, Peterson RKD. Agricultural biotechnology and societal decision-making: the role of risk analysis. AgBioForum 2000;3:291-98.
14. Peterson RKD, Arntzen CJ. On risk and plant-based biopharmaceuticals. Trends in Biotechnology 2004;22:64-6.
15. Kirk DD, McIntosh K, Walmsley AM, Peterson RKD. Risk analysis for plant-made vaccines. Transgenic Research 2005;14:449-62.
16. U.S Food and Drug Administration (FDA). Guidance for industry: drugs, biologics and medical devices derived from bioengineered plants for use in humans and animals. 2002. Available from: URL: http://www.fda.gov/cber/gdlns/ bioplant.pdf - the web site was visited last time on 18 December 2006.
17. ICH (International Conference on Harmonization). Preclinical safety evaluation of biotechnology-derived pharmaceuticals, ICH harmonized tripartite guideline S6. 1997. ICH Secretariat, Geneva, Switzerland.
18. Chikwamba R, Cunnick J, Hathaway D, McMurray J, Mason H, Wang K. A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Research 2002;11:479-93.
19. Humpf HU, Voss KA. Effects of thermal food processing on the chemical structure and toxicity of fumonisin mycotoxins. Molecular Nutrition and Food Research 2004;48:255-69.
20. Chikwamba R, McMurray J, Shou H, Frame B, Pegg SE, Scott P, et al. Expression of a synthetic E. coli heat-labile enterotoxin B sub-unit (LT-B) in maize. Molecular Breeding 2002;10:253-65.
21. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. The Journal of Infectious Diseases 2000;182:302-5.
22. Huang Z, Elkin G, Maloney BJ, Beuhner N, Arntzen CJ, Thanavala Y, et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 2005;23:1851-8.
23. Alvarez ML, Pinyerd HL, Crisantes JD, Rigano MM, Pinkhasov J, Walmsley AM, et al. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine 2006;24:2477-90.
24. Webster DE, Smith SD, Pickering RJ, Strugnell RA, Dry IB, Wesselingh SL. Measles virus hemagglutinin protein expressed in transgenic lettuce induces neutralizing antibodies in mice following mucosal vaccination. Vaccine 2006;24:3538-44.
25. Beyer AJ, Wang K, Umble AN, Wolt JD, Cunnick JE. Low dose exposure and immunogenicity of transgenic maize expressing the Escherichia coli heat-labile toxin B subunit. Environmental Health Perspectives 2007;doi:10.1289/ehp.9687. Available from: URL: http://www.ehponline.org/members/2006/9687/9687.pdf - the web site was visited last time on 18 December 2006.
26. Karaman S, Cunnick J, Wang K. Analysis of immune response in young and aged mice vaccinated with corn-derived antigen against Escherichia coli heat-labile enterotoxin. Molecular Biotechnology 2006;32:31-42.
27. Landry TD, Chew L, Davis J, Frawley N, Stelman SJ, Thomas J, et al. Safety evaluation of archaeal a-amylase (BD 5088) enzyme preparation expressed by Pseudomonas fluorescens Biovar I. Regulatory Toxicology and Pharmacology 2003;37:149-68.
28. Goodman RE, Hefle SL, Taylor SL, van Ree R. Assessing genetically modified crops to minimize the risk of increased food allergy: a review. International Archive of Allergy and Immunology 2005;137:153-66.
29. Prescott VE, Hogan SP. Genetically modified plants and food hypersensitivity diseases: usage and implications of experimental model for risk assessment. Pharmacology and Therapeutics 2006;111:374-83.
30. Metcalfe DD. Introduction: what are the issues in addressing the allergenic potential of genetically modified foods? Environmental Health Perspectives 2003;111:1110-3.
31. Mari A, Riccioli D. The allergome web site - a database of allergenic molecules: aim, structure, and data of a web-based resource. Journal of Allergy and Clinical Immunology 2004;113:S301.
32. Pearson WR and Lipman DJ. Improved tools for biological sequence comparison. Proceedings of the National Academy of Science of the United States of America 1988;85:2440-8.
33. Howard JA, Donelly KC. A quantitative safety assessment model for transgenic protein products produced in agricultural crops. Journal of Agricultural and Environmental Ethics 2004;17:545-58.
34. Shirai T, Shimota H, Chida K, Sano S, Takeuchi Y, Yasueda H. Anaphylaxis to aprotinin in fibrin sealant. Internal Medicine 2005;44:1088-9.
35. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. New England Journal of Medicine 2006;354:353-65.
36. Christensen P, Misra MK, Rai S, Shyy Y-Y, Wolt JD. Confined production processes for non-food corn. Biosafety Institute for Genetically Modified Agricultural Products, Iowa State University, Ames, IA 2005.
37. Wolt JD, Shyy YY, Christensen PJ, Dorman KS, Misra M. Quantitative exposure assessment for confinement of maize biogenic systems. Environmental Biosafety Research 2004;3:183-96.
38. Wolt JD, Wang K, Peterson RKD. Risk of unintended antigen occurrence in food: a case instance for maize-expressed LT-B. Journal of Human and Ecological Risk Assessment 2006;12:856-70.
39. US Food and Drug Administration (FDA). Approaches to establish thresholds for major food allergens and for gluten in food. The Threshold Working Group. March 2006. Available from: URL: http://www.cfsan.fda.gov/~dms/alrgn2.html - the web site was visited last time on 18 December 2006.
40. Devos Y, Reheul D, De Schrijver A. The co-existence between transgenic and non-transgenic maize in the European Union: a focus on pollen flow and cross-fertilization. Environmental Biosafety Research 2005;4:71-87.
41. Streatfield SJ. Regulatory issues for plant-made pharmaceuticals and vaccines. Expert Review of Vaccines 2005;4:5901-6010.
42. Council for Agricultural Science and Technology. Evaluation of the US regulatory process for crops developed through biotechnology. 2001; Issue Paper 19. Ames, IA, USA.
43. Conner AJ, Glare TR, Nap JP. The release of genetically modified crops into the environment. Part II. Overview of ecological risk assessment. Plant Journal 2003;33:19-46.
44. Nielsen KM, Townsend JP. Monitoring and modeling horizontal gene transfer. Nature Biotechnology 2004;22:1110-4.
45. Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, Rideout BA, et al. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 2004;427:630-3.
46. Ridsdill-Smith TJ. Effects of avermectin residues in cattle dung on dung beetle (Coleoptera: Scarabaeidae) reproduction and survival. Veterinary Parasitology 1993;48:127-37.
47. US Food and Drug Administration (FDA). Guidance for industry: environmental assessment of human drug and biologics applications. Center for Drug Evaluation Research 1998.
48. US Department of Agriculture-Animal and Plant Health Inspection Services. Risk assessment outline for use in preparing risk analyses for biotechnology-derived products. Center for Veterinary Biologics, October 2005. Available from: URL: http://www.aphis.usda.gov/vs/cvb/lpd/RiskAssessmentOutline. pdf - the web site was visited last time on 18 December 2006.
49. Romeis J, Meissle M, Bigler F. Transgenic crops expressing Bacillus thuringiensis toxins and biological control. Nature Biotechnology 2006;24:63-71.
50. Parmenter DL, Boothe JG, van Roojen GJ, Yeung EC, Moloney MM. Production of biologically active hirudin in plant seeds using oleosin partitioning. Plant Molecular Biology 1995;29:1167-80.
51. Smyth S, Khachatourians G, Phillips PWB. In: Evenson RE and Santeniello V, editors. Governing Innovative Science: Challenges Facing the Commercialization of Plant-made Pharmaceuticals. CABI Publishing, Oxfordshire, UK; 2006:133-46.
52. Mariani C, Goldberg RB, Leemans J. Engineered male sterility in plants. Symposia of the Society for Experimental Biology 1991;45:271-9.
53. Ruiz ON, Daniel H. Engineering cytoplasmic male sterility via the chloroplast genome by expression of {beta}-ketothiolase. Plant Physiology 2005;138:1232-46.
54. Ruiz ON, Hussein HS, Terry N, Daniell H. Phytoremediation of organomercurial compounds via chloroplast genetic engineering. Plant Physiology 2003;132:1344-52.
55. Daniell H, Datta R, Varma S, Gray S, Lee SB. Containment of herbicide resistance through genetic engineering of the chloroplast genome. Nature Biotechnology 1998;16:345-8.
56. Daniell H. Molecular strategies for gene containment in transgenic crops. Nature Biotechnology 2002;20:581-6.
57. Raybould A, Cooper I. Tiered tests to assess the environmental risk of fitness changes in hybrids between transgenic crops and wild relatives: the example of virus resistant Brassica napus. Environmental Biosafety Research 2005;4:127-40.
58. Bartsch D, Cuguen J, Biancardi E, Sweet J. Environmental implications of gene flow from sugar beet to wild beet - current status and future research needs. Environmental Biosafety Research 2003;2:105-15.
59. Fuchs M, Chirco EM, Gonsalves D. Movement of coat protein genes from a commercial virus-resistant transgenic squash into a wild relative. Environmental Biosafety Research 2004;3:5-16.
60. Davison J. Genetic exchange between bacteria in the environment. Plasmid 1999;42:73-91.
61. Schluter K, Futterer J, Potrykus I. Horizontal gene transfer from a transgenic potato line to a bacterial pathogen (Erwinia chrysanthemi) occurs - if at all - at an extremely low frequency. Biotechnology (NY) 1995;13:1094-8.
62. Pettersen A, Bøhn T, Primicerio R, Shorten PR, Soboleva TK, Nielsen KM. Modelling suggests frequency estimates are not informative for predicting the long-term effect of horizontal gene transfer in bacteria. Environmental Biosafety Research 2005;4:223-33.
63. Life Sciences World. $51 Billion Protein Therapeutics Market set to Reach $87 Billion by 2010, December 6, 2006. Available from: URL: http://www.lifesciencesworld.com/news/view/7533 - the site was visited last time on 18 December 2006.
64. Graff G, Moschini G. Pharmaceuticals and industrial products in crops: economic prospects and impact on agriculture. Iowa Ag Review 2004;10:4-11.
65. Miller HI, Longtin D. Down on the Biopharm. Policy Review December 2003 and January 2004;122.
66. Moschini G. Pharmaceutical and industrial traits in genetically modified crops: co-existence with conventional agriculture. The American Journal of Agricultural Economics 2006;88:1184-92.
67. Herzmann DE, Wolt J, Arritt R, Westgate M, Goggi S. Modeling out crossing probabilities for maize in Iowa. Abstracts, ASA-CCCA-SSSA International Annual Meetings, 12-16 Novemeber 2006, Indianapolis, IN. 2006; 166-7.